$-0.25 EPS Expected for DelMar Pharmaceuticals Inc (DMPI)

September 7, 2017 – By Marguerite Chambers

 $ 0.25 EPS Expected for DelMar Pharmaceuticals Inc (DMPI)

Analysts await DelMar Pharmaceuticals Inc (NASDAQ:DMPI) to report earnings on September, 12. They expect $-0.25 EPS, down 47.06 % or $0.08 from last year’s $-0.17 per share. After $-0.18 actual EPS reported by DelMar Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 38.89 % negative EPS growth. The stock decreased 10.16% or $0.13 on September 6, reaching $1.15. About shares traded. DelMar Pharmaceuticals Inc (NASDAQ:DMPI) has declined 57.32% since September 7, 2016 and is downtrending. It has underperformed by 74.02% the S&P500.

DelMar Pharmaceuticals, Inc. is a clinical-stage drug development company. The company has market cap of $17.23 million. The Firm focuses on the treatment of cancer. It currently has negative earnings. The Firm is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme , a form of brain cancer.

More notable recent DelMar Pharmaceuticals Inc (NASDAQ:DMPI) news were published by: Seekingalpha.com which released: “DelMar Pharmaceuticals: Where We Are Headed” on August 08, 2017, also Seekingalpha.com with their article: “Patients, The Center Of Our Efforts” published on August 17, 2017, Seekingalpha.com published: “DelMar Pharmaceuticals – The $2 Biotech Stock That Could Win Brain Cancer Fight” on August 01, 2017. More interesting news about DelMar Pharmaceuticals Inc (NASDAQ:DMPI) were released by: Prnewswire.com and their article: “DelMar Pharmaceuticals Appoints Saiid Zarrabian to the Board of Directors and …” published on July 11, 2017 as well as Prnewswire.com‘s news article titled: “DelMar Pharmaceuticals to Present at the 19th Annual Rodman & Renshaw Global …” with publication date: September 06, 2017.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.